Abbott Laboratories is unveiling a coronavirus test that can tell if someone is infected in as little as 5 minutes, and is so small and portable it can be used in almost any healthcare setting.
The medical-device maker plans to supply 50,000 tests a day starting April 1, said John Frels, vice president of research and development at Abbott Diagnostics. The molecular test looks for fragments of the coronavirus genome, which can be detected in as little as five minutes when it is present at high levels. A thorough search to definitively rule out an infection can take up to 13 minutes, he said.
The U.S. has struggled to supply enough tests to detect the coronavirus, even as the outbreak threatens to overwhelm hospitals in New York, California, Washington, and other regions. After initially restricting testing to high-risk people, and problems with a test designed by the Centers for Disease Control and Prevention, U.S. regulators have rushed out diagnostics made by the world’s leading commercial-testing companies.
“This is really going to provide a tremendous opportunity for front-line caregivers, those having to diagnose a lot of infections, to close the gap with our testing,” Frels said. “A clinic will be able to turn that result around quickly, while the patient is waiting.”
The technology builds on Illinois-based Abbott’s ID Now platform, the most common point-of-care test currently available in the U.S., with more than 18,000 units spread across the country. It is widely used to detect influenza, strep throat, and respiratory syncytial virus, a common bug that causes cold-like symptoms.
The test starts with taking a swab from the nose or the back of the throat, then mixing it with a chemical solution that breaks open the virus and releases its RNA. The mixture is inserted into an ID Now system, a small box weighing just under 7 pounds that has the technology to identify and amplify select sequences of the coronavirus genome and ignore contamination from other viruses.
The equipment can be set up almost anywhere, but the company is working with its customers and the Trump administration to ensure the first cartridges used to perform the tests are sent to where they are most needed. They are targeting hospital emergency rooms, urgent-care clinics and doctors’ offices.
Last week, Abbott’s m2000 RealTime system got U.S. Food and Drug Administration approval for use in hospitals and molecular laboratories to diagnose the infection. That system can churn through more tests on a daily basis, up to 1 million a week, but it takes longer to get the results. Abbott plans to provide at least 5 million tests a month between the two systems.
Other companies are also rolling out faster testing systems. Henry Schein Inc. on Thursday said its point-of-care antibody test, which looks for evidence a person’s immune system has already fought off the infection, was available. The blood test can be given at the point of care and delivers results in about 15 minutes, though it cannot be used to definitively diagnose a current infection.
© Copyright 2020 Bloomberg News. All rights reserved.
